10 Visuals That Will Change Your Life 1.

🚨 Very happy to announce the publication of the EXPERT CONSENSUS for the treatment of RARE #LUPUS MANIFESTATIONS ⬇️ in The Lancet Rheumatology, right in time for the session scheduled TOMORROW Saturday 9am at Lupus 2025 #Lupus2025 Toronto 👍 thelancet.com/journals/lanrh…

Lupus panniculitis Laurent ARNAUD #EULAR2025

Key summary slide of research in the use of CD19 CAR T cells in rheumatology indications Dinesh Khanna Dr. John Cush #EULAR2025

CONGRESS | #EULAR2025 | PRESENTATION Laurent Arnaud, Laurent ARNAUD, Strasbourg University Hospitals, discussed the ERN ReCONNET-SLICC-SLEuro expert consensus on treating rare manifestations in #lupus. · 45 unique rare SLE manifestations have been identified; 21 were selected

🧵 Top 10 Labs in Rheumatology — And How to Interpret Them Ordering is easy. Interpreting in context is where clinical medicine begins 👇 #Rheumatology #MedTwitter Dr Ihab Suliman Dr. Akhil 🇮🇳

✅ Why are we suddenly getting so many updated #lupus recommendations? (15+ in the last 5 years!!) ⬇️ by various groups worldwide 🌍🌎🌏 #NEDAI2025

Potential New Future Therapies in #SLE #Lupus [Dr Antonis Fanouriakis] EULAR2025 #Rheumatology

🧵 Thread: Reproductive Rheumatology in India—Insights from a New Survey of Rheumatologists 🇮🇳 Study by Vinod Ravindran sir et al. mjrheum.org/current-issue/… #MedTwitter Dr Ihab Suliman

Tobin and Cooper review #InbornErrorsOfImmunity that can present with rheumatologic and #autoimmune complications and the role of genetic testing for establishing a molecular diagnosis & devising personalized treatment plans to improve patient outcomes. hubs.la/Q03yv0n00

ICYMI, our review article about antiphospholipid syndrome in ACR_Journals is now nicely formatted (and remains free) Antiphospholipid Syndrome: An Antibody-Mediated Disease With Emerging Therapeutic Opportunities 🔮💊💉 👀 Link in the replies...

Mixed connective tissue disease - By Kevin Chevalier (fellow in Internal Medicine, Paris, France) #MCTD #Sharp #RNP #InternistAcademy 2025

Anti-Ku antibodies in connective tissue diseases - By Marie Robert (fellow in Internal Medicine, Paris, France) #Ku #InternistAcademy 2025

HCQ → 🔑 for CHB prevention in Ro⁺ preg Fetal ❤️ monitoring → early dx 1st° block → short fluo GC 2nd° block → GC ± IVIG 3rd° block → if EFE/hydrops/poor function → GC + IVIG ± plasmaph If stable → no therapy HCQ = cornerstone,for severe cases #ACR25 #ACRAmbassador

👉Diagnostic utility of Type 1 IFN marker in DM from other myositis . 🧬MxA,ISG15, RIG1 upregulation in DM ⚡⚡MxA perifascicular while ISG15 & RIG1 focal or scattered sarcoplasmic distribution. ✊Study from #NIMS , Hyderabad ✊A proud moment for India #ACR2025 #ACRambassador

🔥 Fever + Cytopenia — a diagnostic minefield. When every line on the CBC tells a story, can you decode the underlying rheumatic or immune cause? 👇 #RheumTwitter #MedTwitter #RheumRounds #ClinicalPearls #Autoimmunity #Immunology #Rheumatology #MedEd #HemeRheum #DermRheum

#ACR25 Abstract 1526 “Guidance for #Steroid Tapering in Systemic Lupus Erythematosus” 101 international experts reached Delphi consensus on CS tapering strategies in #SLE. 🔹 Practical guidance for real-world tapering across disease activity levels and organ involvement.

Congratulations Durga Prasanna Misra Sir 🙏🏻 Takayasu Arteritis — Nature Reviews Rheumatology 2025 (by Dr Durga P. Misra & Team ) 1️⃣ About: Takayasu arteritis (TAK) — rare, chronic large-vessel vasculitis targeting the aorta & its major branches, predominantly affecting young women

🔥 GRAPPA: New Definitions for Difficult PsA • C2M-PsA: Ongoing symptoms after ≥1 b/tsDMARD, driven by complexity → comorbidities, chronic pain, obesity, fibromyalgia, mental health, access issues. • TR-PsA: True refractory inflammation → failure of ≥3 MoAs (≥2

New content online: PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease bit.ly/3Mi5erF